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I have read with great interest Dr. Pehlivan (1) et al.’s
paper entitled “Maternal serum vitamin D levels in the
third trimester of pregnancy”, since we did similar studies
in 1981 as cited by the authors (2). Low 25hydroxycholecalciferol [25 (OH) CC] levels were found in
20% of the mothers who delivered in winter months but
not in summer month deliveries in our study. The authors
stated that 79.5% of the mothers had severe 25 (OH) CC
deficiency and cited other studies from ‹stanbul and
Ankara with low 25 (OH) CC levels in 66.6% of women
of reproductive age and 85% of mothers who delivered
in October and November. These findings indicated that
low 25 (OH) CC levels in women are not related only to
Kocaeli but to the whole of Turkey, most likely. This is
very alarming since low 25 (OH) CC in women is
increasing since our study if it was not a low estimation
of the situation by us. On the other hand, we have to
determine our standard 25 (OH) CC levels. These
documentations may indicate that studies in our
universities are theoretical and not related to the solution
of our medical problems, since the deficiency is increased
among pregnant women.
Actually the purpose of publications should be to
reform medical thoughts and practice through new
information. This is especially required in developing
countries such as Turkey.
Since 75.6% of the women in the authors’ study
received antenatal medical care, I would like to learn

whether 25 (OH) CC levels were found higher in this
group than in the group that received no care?
The authors also stated that “No difference was
detected between 25 hydroxy D3 levels and daily
exposure to sunlight (p > 0.05)”. If this is correct, how
could the dressing effect be considered?
Was it somehow less reflected statistically because
there were only 4 women in group I?
On this occasion, I would like to mention that in
addition to cholecalciferol and parathyroid hormone, low
density lipoprotein receptor related protein 5 (LRP 5) and
osteoprotegerin should also be taken into consideration
for bone mineralization (3-6).
Lastly 1 would repeat my question “How long has
cholecalciferol been called vitamin D?”, since it is not a
vitamin (7).
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